Congenital Ichthyosis
Phase 3 study of TMB-001 for treatment of congenital ichthyosis fails to meet endpoints
Timber Pharmaceutical’s study investigating the use of a new topical ointment formulation of isotretinoin for moderate to severe congenital ichthyosis did not achieve its endpoints, LEO Pharma announced in a press release.
LEO Pharma acquires Timber Pharmaceutical’s bankruptcy assets including TMB-001
Following the bankruptcy of Timber Pharmaceuticals, LEO Pharma has finalized the acquisition of TMB-001 and other assets from Timber, according to a press release.
Topical isotretinoin ointment shows ‘reassuring’ efficacy, safety in congenital ichthyosis
Two formulations of a novel topical isotretinoin ointment formulation were associated with improvements over vehicle in patients with two types of congenital ichthyosis, according to a study.
European Commission grants second orphan drug designation for TMB-001
The European Commission has granted orphan drug designation for TMB-001 for the treatment of X-linked recessive ichthyosis, Timber Pharmaceuticals announced in a press release.
VIDEO: Topical isotretinoin efficacious in congenital ichthyosis
MILAN — Timber Pharmaceuticals Chief Medical Officer Alan Mendelsohn, MD, discusses TMB-001, a topical isotretinoin formula in development for congenital ichthyosis, at the European Academy of Dermatology and Venereology Congress.
TMB-001 yields encouraging results in congenital ichthyosis subtypes
A novel isotretinoin ointment formulation to treat congenital ichthyosis subtypes demonstrated promising results in the phase 2b CONTROL study, according to a research letter published in the Journal of the American Academy of Dermatology.
Timber initiates phase 3 trial of topical isotretinoin for congenital ichthyosis
FDA grants breakthrough designation to Timber’s congenital ichthyosis candidate
Fast track granted for Timber’s congenital ichthyosis candidate
VIDEO: Timber Pharmaceuticals’ topical isotretinoin shows promise in congenital ichthyosis
BOSTON — Timber Pharmaceuticals Chief Medical Officer Alan Mendelsohn, MD, discusses the company’s topical drug candidate for the treatment of congenital ichthyosis at the American Academy of Dermatology Annual Meeting.